Alina Tudorica1, Karen Y Oh1, Stephen Y-C Chui1, Nicole Roy1, Megan L Troxell1, Arpana Naik1, Kathleen Kemmer1, Yiyi Chen1, Megan L Holtorf1, Aneela Afzal1, Charles S Springer, Jr1, Xin Li1, and Wei Huang1
DCE-MRI was performed in 28 breast cancer patients (29 tumors) before, during, and after neoadjuvant chemotherapy (NACT). Several DCE-MRI pharmacokinetic (PK) parameters were found to be good early predictors of pathologic complete response (pCR) vs. non-pCR after only one NACT cycle. In addition, several PK parameters and tumor size were significantly correlated with pathologically measured residual cancer burden (RCB).